Beta Bionics, Inc. Common Stock
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is developing Patch P… Read more
Beta Bionics, Inc. Common Stock (BBNX) - Total Assets
Latest total assets as of December 2025: $328.74 Million USD
Based on the latest financial reports, Beta Bionics, Inc. Common Stock (BBNX) holds total assets worth $328.74 Million USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Beta Bionics, Inc. Common Stock - Total Assets Trend (2022–2025)
This chart illustrates how Beta Bionics, Inc. Common Stock’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Beta Bionics, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Beta Bionics, Inc. Common Stock's total assets of $328.74 Million consist of 81.5% current assets and 18.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.6% |
| Accounts Receivable | $17.12 Million | 5.2% |
| Inventory | $21.72 Million | 6.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Beta Bionics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Beta Bionics, Inc. Common Stock's current assets represent 81.5% of total assets in 2025, an increase from 80.1% in 2022.
- Cash Position: Cash and equivalents constituted 9.6% of total assets in 2025, down from 77.9% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is inventory at 6.6% of total assets.
Beta Bionics, Inc. Common Stock Competitors by Total Assets
Key competitors of Beta Bionics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Beta Bionics, Inc. Common Stock - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Beta Bionics, Inc. Common Stock generates 0.30x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Beta Bionics, Inc. Common Stock is currently not profitable relative to its asset base.
Beta Bionics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.66 | 6.29 | 9.77 |
| Quick Ratio | 7.96 | 5.66 | 9.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $236.98 Million | $ 111.78 Million | $ 93.02 Million |
Beta Bionics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Beta Bionics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.08 |
| Latest Market Cap to Assets Ratio | 0.97 |
| Asset Growth Rate (YoY) | 119.7% |
| Total Assets | $328.74 Million |
| Market Capitalization | $318.82 Million USD |
Valuation Analysis
Near Book Valuation: The market values Beta Bionics, Inc. Common Stock's assets close to their book value ( 0.97x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Beta Bionics, Inc. Common Stock's assets grew by 119.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Beta Bionics, Inc. Common Stock (2022–2025)
The table below shows the annual total assets of Beta Bionics, Inc. Common Stock from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $328.74 Million | +119.68% |
| 2024-12-31 | $149.65 Million | +35.99% |
| 2023-12-31 | $110.04 Million | +209.74% |
| 2022-12-31 | $35.53 Million | -- |